Dr. Axe Wire · Food, herbs & supplements · health
Could This Traditional Chinese Herbal Blend Help Protect Diabetic Kidneys?
A two-herb traditional Chinese formula lowered blood sugar and kidney injury markers in diabetic rats, pointing to a possible mechanism.

- What they found: A classic Chinese herbal formula called Danggui Buxue Decoction eased kidney damage and scarring in diabetic rats.
- Who was studied: In rats.
- What it doesn't show: Whether it works the same way in people.
A classic Chinese herbal formula called Danggui Buxue Decoction eased kidney damage and scarring in diabetic rats, according to a study published November 19, 2026 in the Journal of Ethnopharmacology.
Researchers fed rats a high-fat, high-sugar diet plus a low dose of streptozotocin to induce diabetic kidney disease, then treated some with Danggui Buxue Decoction, a traditional formula combining astragalus root (huang qi) and dong quai (dang gui). Treated rats had lower blood glucose, HbA1c, creatinine and blood urea nitrogen than untreated diabetic rats, plus less kidney tissue injury and collagen buildup, a marker of scarring called tubulointerstitial fibrosis.
The same pattern appeared in human kidney cells grown in a lab dish and exposed to high glucose. A computational screen separately found 148 overlapping targets shared between the formula's compounds and diabetic kidney disease, flagging two, GSK-3β and CCND1, as central nodes.
The authors linked treatment to higher GSK-3β Ser9 phosphorylation, a modification that restrains the protein's activity, and to changes in markers of epithelial-mesenchymal transition, where kidney lining cells take on scar-forming traits. Blocking or altering this pathway with other compounds in the kidney cells changed the formula's effects, which the authors say supports GSK-3β/CCND1 signaling as a contributor to the kidney-protective pattern.
DBD attenuated DKD-associated renal injury and tubulointerstitial fibrosis, accompanied by modulation of GSK-3β/CCND1 signaling
This animal and lab-dish study reported no sample sizes or human participants, so dosing, safety and effectiveness in people with diabetic kidney disease remain untested. The 148 shared targets came from a computational prediction model, not a measured outcome. Larger animal and eventually human studies are the next step.
Dr. Axe’s Take
This mechanism study points to GSK-3β and CCND1, two switches that help decide whether kidney cells heal or scar, as a plausible reason traditional Chinese medicine has paired astragalus and dong quai for kidney and blood conditions. I wouldn't treat this as proof the formula works in people with diabetic kidney disease yet. For blood sugar and kidney support, I'd focus on what's established: a whole-food, lower-glycemic diet, cinnamon and bitter melon in cooking, and adequate hydration and resistance training to improve insulin sensitivity. If you have diabetic kidney disease, keep taking any prescribed medication exactly as directed and work with your nephrologist before adding any herbal approach.
— Dr. AxeTake the Metabolic Health Quiz →
Story summary
- Who
- Rats with diet- and streptozotocin-induced diabetic kidney disease; human kidney (HK-2) cells treated with high glucose. Sample size not reported.
- Design
- Network pharmacology, molecular docking and HPLC-DAD fingerprinting combined with an animal model and a cell study; DBD-treated versus untreated diabetic groups.
- Dose
- Not reported
- Primary result
- DBD-treated rats had lower blood glucose, HbA1c, creatinine and blood urea nitrogen, plus less tubular injury and collagen deposition, than untreated diabetic rats.
- Secondary
- 148 overlapping targets identified between DBD and diabetic kidney disease, with GSK-3β and CCND1 as core nodes; higher GSK-3β Ser9 phosphorylation and CCND1 expression with treatment in rat kidneys and HK-2 cells.
- Funding / conflicts
- Funders listed in the journal record: National Natural Science Foundation of China; Heilongjiang University of Chinese Medicine; Department of Science and Technology of Heilongjiang Province; Heilongjiang Province Natural Science Foundation. Competing interests: Declaration of Competing Interest ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
- Date
- Nov 19, 2026


